AKB 9778

Drug Profile

AKB 9778

Alternative Names: AKB-9089; AKB-9778; AKB-9875; HPTP-beta mAb - Aerpio

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procter & Gamble
  • Developer Aerpio Pharmaceuticals; Akebia Therapeutics; Duke University; Harvard Medical School; Johns Hopkins University School of Medicine; Massachusetts General Hospital; Massachusetts Institute of Technology; Max Planck Institute for Molecular Biomedicine; New York University
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors; TIE-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion
  • No development reported Age-related macular degeneration; Breast cancer

Most Recent Events

  • 06 Sep 2017 Active development is ongoing for Diabetic macular oedema (Adjunctive treatment, Monotherapy) in USA (NCT02050828)
  • 06 Sep 2017 AKB-9778 is still in phase II trials for Retinal vein occlusion (In adults, In the elderly) in USA (SC) (NCT02387788)
  • 06 Sep 2017 No development reported - Preclinical for Age-related macular degeneration in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top